- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic migraine
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 803KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 177KB)
Eptinezumab – July 2022
Eptinezumab: Solution concentrate for I.V infusion 100 mg in 1 mL; Vyepti®
Last updated
28 October 2022